Company: STAA
Filing Date: 2025-12-08
Form Type: DEFA14A
Source: 0001193125-25-310637
Chunk: 4

Company: STAAR SURGICAL CO
Filing Date: 2025-12-08
Form: DEFA14A
Chunk 4
---
 expected timeframes or at all;
(4) risks related to disruption of management’s attention from the Company’s ongoing business operations due to the proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of the
Company to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6) the ability of the Company to meet expectations
regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against the Company related to the proposed transaction; (8) the possibility that the Company’s stock price may
decline significantly if the proposed transaction is not consummated; and (9) other important factors set forth in the Proxy Statement under the caption “Risk Factors” and the Company’s Annual Report on Form 10-K for the year ended December 27, 2024 under the caption “Risk Factors,” as any such factors may be updated from time to time in the Company’s other filings with the SEC.

Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, the Company undertakes no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

-3-

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: December 8, 2025 |     | STAAR Surgical Company 
 By:                    |     | /s/ Stephen C. Farrell  |
|:-----------------------|:----|:-----------------------|:----|:------------------------|
|                        |     | Name:                  |     | Stephen C. Farrell      |
|                        |     | Title:                 |     | Chief Executive Officer |

-4-

Exhibit 99.1

STAAR Surgical Announces Expiration of Go-ShopPeriod

No Competing Acquisition Proposals Received

Results of Go-ShopProcess Validate the Effectiveness of the STAAR Board’s Process

Now is the Right Time to Sell the Business and Alcon is the Right Buyer

LAKE FOREST, Calif, December8, 2025– STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO
family of Im